Claim Missing Document
Check
Articles

Found 2 Documents
Search

Biomarkers Of CRP, IL-6, And D-dimer Covid-19 Patients That Are Giving Convalence Plasma Therapy – Literature Review Rofiq, Ainul; Mahendra, Reza Hery; Bastiana; Tunjungsari, Yekti
Jurnal Medis Islam Internasional Vol 3 No 1 (2021): December
Publisher : UNUSA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33086/iimj.v3i1.2532

Abstract

Background: Convalescent plasma therapy is the only antibody-based therapy used to treat COVID-19 Patients. The use of convalescent plasma therapy has been recommended by the Food and Drug Administration (FDA) as a therapy for COVID-19 patients (FDA in Asep, 2020). Several routine biomarker parameters used as indicators in the diagnosis of COVID-19 are CRP, IL-6 and D-Dimer. There was a change between the three biomarker values of CRP, IL-6, and D-Dimer between COVID-19 patients on convalescent plasma therapy and COVID-19 patients who did not receive convalescent plasma therapy. This review article is how effective the use of convalescent plasma as therapy for COVID-19 patients is by looking at changes in the biomarkers of CRP, IL-6 and D-Dimer in patients receiving convalescent plasma therapy. Methode: This literature review uses 3 fulltext articles obtained by combining keywords in an electronic database: Scopus, Cochrane Library, PubMed, and Google Scholar. Articles were eliminated using predefined inclusion and exclusion criteria, then analyzed systematically. The preparation of the discussion uses a systematic analysis based on the themes and topics of discussion obtained in the research article. Conclussions: There were changes in the biomarker values of CRP, IL-6 and D-Dimer in COVID-19 patients who received convalescent plasma therapy and COVID-19 patients who did not receive convalescent plasma therapy. Keywords: D-Dimer level, Interleukin 6 (IL-6) level, C-Reactive protein (CRP) level, plasma konvalesen, dan outcomes pasien COVID-19
Antidepressant Effects of Mitragyna Speciosa Korth Extract on Diabetic Rats Putra, Reza Hery Mahendra; Awwaliyah, Evi Sylvia; Salim, Hotimah Masdan; Alam, Ilham Putera; Rofiq, Ainul
Jurnal Ilmu Kesehatan dan Kesehatan Vol 8 No 02 (2024): AUGUST
Publisher : UNUSA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33086/mhsj.v8i02.5919

Abstract

Background: Diabetes mellitus is most common associated with neurological complications, including depressive symptoms, so this study investigated whether mitragyna may provide benefits in reducing depressive symptoms in animal models of diabetes. This study aims to evaluate the effect of mitragyna as a potential antidepressant agent in animal models of diabetes mellitus using the Force Swimming Test (FST). Methods: In this study, diabetes mellitus rats were induced by administering streptozotocin and then divided into four groups: control group (Control), Group Diabetes (DM), Mitragyna treatment group (DM+EMS 15mg) and (DM+EMS 30mg). After the treatment period, the rats were then tested with the FST, which is used to measure immobility behavior which can be used as an indicator of depressive symptoms. Results: The results showed that the treatment group that received mitragyna showed shorter immobility times compared to the control group (P<0.01), indicating an increased active response in facing FST stressors. Conclusion: These results indicate that mitragyna has potential as an antidepressant agent in reducing depressive symptoms in rats models of diabetes mellitus.